Pia Gideon new Board member of Devyser
Stockholm, September 30, 2021 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that Pia Gideon was elected as a new Board member at the Extraordinary General Meeting held on September 30, 2021.
Pia Gideon (born 1954) has extensive experience from various senior positions in Sweden and internationally in marketing, communication and leadership development. Pia has been active for 20 years as the Chairman and member of boards for listed and state-owned companies, specializing in technology and healthcare. Her other current assignments comprise Chairperson of Qlucore AB and Board member of Guard Therapeutics AB, Apoteket AB and Gideon & Partners AB. Pia holds an M.Sc. in Economics from Stockholm School of Economics.
“We are very pleased to that Pia is joining us on Devyser’s Board of Directors. Her broad experience and considerable expertise in commercialization and marketing will be extremely valuable for Devyser as we continue to expand to new markets and are increasingly transitioning to direct sales,” comments Mia Arnhult, Chairman of the Board of Devyser.
Pia Gideon is independent in relation to the company’s major shareholders, the company and company management, and currently owns no shares or other financial instruments in the company.
In addition to Pia Gideon, Devyser’s Board is comprised of Mia Arnhult, Lars Höckenström, Ulf Klangby and Fredrik Dahl, with Mia Arnhult as Chairman of the Board. Fredrik Dahl was elected as Board member at Devyser’s Annual General Meeting on May 27, 2021.
For more information, please contact:
Fredrik Alpsten, CEO of Devyser Diagnostics AB (publ)
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106
About Devyser Diagnostics AB (publ)
Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold in more than 45 countries. The products are used for complex DNA testing within oncology, hereditary diseases and transplantation. The products are used to guide targeted cancer therapies, to enable a wide array of genetic tests, as well as in post-transplant follow-up. Devyser’s product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.
For more information, please visit www.devyser.com.